(RADAR-CNS) RADAR EPILEPSY Study 2
Research type
Research Study
Full title
Remote assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS) RADAR EPILEPSY Study 2.
IRAS ID
263016
Contact name
Mark Richardson
Contact email
Sponsor organisation
King's College London
Duration of Study in the UK
1 years, 2 months, 0 days
Research summary
The last decade has seen an explosion in the capability of monitoring individuals via sensors in smartphones or wearable devices. The development of remote measurement technologies (RMT) is an innovation which could be used to predict and avert negative clinical outcomes by providing real-time information on the patient’s current clinical state, as well as providing predictive information indicative of future deterioration. RMT appears particularly interesting for those chronic conditions whose course is dynamic and characterized by multiple relapses in parameters that could be measured remotely and passively via unobtrusive on-body biosensors and smartphones. Epilepsy is one of the most common neurological disorders, affecting about 0.6% of the population worldwide and 1% in the United Kingdom (UK). It is characterized by recurrent seizures which are mostly unprovoked and unpredictable. The potential application of bio-signals obtained from non-EEG sensors and the use of smartphone app to collect real time data about patient mood,cognition,activity,social interactions and medication use in seizure detection will assume great importance. We will recruit patients with epilepsy from the Epilepsy Service and the Clinical Neurophysiology Department at King’s College Hospital (KCH).Participants will be asked to wear continuously at home a non-invasive device for 24h/day for the entire duration of the study (6 months) and complete every day questionnaires and cognitive tasks using an aRMT smartphone app. The first aim of the study is to determine the usability, feasibility and acceptability of the RMT procedure. This study will also estimate if multi-parametric RMT collected in populations with epilepsy can prospectively estimate variations in seizure occurrence and other outcomes. This project is an integral part of RADAR-CNS which receives funding from the Innovative Medicines Initiative 2 Joint.Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
REC name
London - Bromley Research Ethics Committee
REC reference
19/LO/1884
Date of REC Opinion
16 Jan 2020
REC opinion
Further Information Favourable Opinion